EQS-News: MEDICLIN AG / Key word(s): Expansion/Contract MEDICLIN: Transfer of operations of Reha-Klinik am Sendesaal to MEDICLIN took place on 1 May 02.05.2024 / 17:14 CET/CEST The issuer is solely responsible for the content of this announcement. Offenburg, 2 May 2024
MEDICLIN: Transfer of operations of Reha-Klinik am Sendesaal to MEDICLIN took place on 1 May Offenburg, 2 May 2024: On 1 May, the operation of the Reha-Klinik am Sendesaal was transferred to MEDICLIN. A symbolic handover of the key between MEDICLIN COO Thomas Piefke, clinic managing director and regional managing director Holger Kammann and Heinz Beekmann, managing director of the Specht Group, took place on Monday. Beekmann presented the “Bremen Key” made of acrylic glass to the MEDICLIN representatives in front of the rehabilitation clinic. At the beginning of April, representatives of MEDICLIN and the Specht Group signed the purchase agreement for the clinic. The clinic will now operate under the name “MEDICLIN Reha-Klinik am Sendesaal”. “We extend a warm welcome to the employees in Bremen,” says MEDICLIN CEO Dr Joachim Ramming. “MEDICLIN has facilities throughout Germany in various areas – rehabilitation, acute care, nursing care, MVZs – but our core competence is and remains rehabilitation.” Piefke adds: “We want to continue to grow in the rehabilitation sector, both inpatient and outpatient. We are delighted that the Reha-Klinik am Sendesaal is now part of the MEDICLIN family!” For further information: MEDICLIN Aktiengesellschaft Investor Relations Public Relations About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510) MEDICLIN ─ a company of the Asklepios Group 02.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study | Psychedelic Finance
VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian